1 |
|
Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics
|
28 |
1.361 |
SuperPathway |
- Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics
|
Pathways |
- Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics
|
|
2 |
|
Type II diabetes mellitus
|
22 |
1.361 |
SuperPathway |
- Type II diabetes mellitus
|
Pathways |
- Type II diabetes mellitus
|
|
3 |
|
Statin Pathway - Generalized, Pharmacokinetics
|
53 |
0.893 |
Pathways |
- Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics
- Anti-diabetic Drug Repaglinide Pathway, Pharmacokinetics
|
|
4 |
|
Vasopressin-like receptors
|
6 |
0.893 |
Pathways |
- Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI)
- Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI)
|
|
5 |
|
Insulin signaling in adipocytes (normal condition)
|
8 |
0.632 |
Pathways |
- Insulin signaling in adipocytes (diabetic condition)
|
|
6 |
|
trehalose degradation
|
11 |
0.632 |
Pathways |
- Defective GCK causes maturity-onset diabetes of the young 2 (MODY2)
|
|
7 |
|
Hepatic ABC Transporters
|
88 |
0.632 |
Pathways |
- MODY (Maturity-Onset Diabetes of Young)
|
|